PortfoliosLab logo
Ascendis Pharma A/S (ASND)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US04351P1012

CUSIP

04351P101

IPO Date

Jan 28, 2015

Highlights

Market Cap

$9.13B

EPS (TTM)

-$6.56

Total Revenue (TTM)

$368.70M

Gross Profit (TTM)

$314.50M

EBITDA (TTM)

-$157.80M

Year Range

$111.09 - $183.00

Target Price

$221.18

Short %

7.76%

Short Ratio

6.88

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Ascendis Pharma A/S (ASND) returned 12.17% year-to-date (YTD) and 15.71% over the past 12 months. Over the past 10 years, ASND delivered an annualized return of 24.57%, outperforming the S&P 500 benchmark at 10.69%.


ASND

YTD

12.17%

1M

2.28%

6M

20.27%

1Y

15.71%

5Y*

2.85%

10Y*

24.57%

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of ASND, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-5.09%19.84%-0.46%9.35%-9.39%12.17%
20243.16%13.72%2.31%-8.42%-2.41%0.95%-2.11%3.71%7.84%-17.74%10.80%1.17%9.31%
20231.60%-10.47%-3.48%-34.75%24.31%2.62%1.01%8.73%-4.47%-4.62%12.45%25.41%3.13%
2022-9.58%-7.60%4.42%-22.23%-7.41%10.00%-7.99%4.72%15.28%11.37%7.01%-0.76%-9.22%
2021-9.97%3.21%-16.84%12.48%-7.30%-2.11%-10.16%32.61%1.70%-4.88%-9.62%-1.82%-19.34%
2020-2.89%-3.49%-13.63%20.53%7.19%1.66%-6.96%7.68%4.14%5.85%3.29%-1.16%19.88%
201914.06%1.90%61.63%-5.37%11.92%-7.63%0.53%-3.22%-14.02%14.80%4.16%20.78%122.06%
201827.23%22.01%5.16%-3.65%14.30%-7.64%2.13%4.47%-0.17%-9.27%5.01%-7.20%56.39%
20175.93%37.92%-5.31%5.43%-19.21%16.39%1.59%-0.85%29.65%-6.26%9.18%7.98%97.92%
20163.93%-8.88%6.92%-9.06%-18.55%-3.42%8.52%28.06%9.00%-3.13%5.44%-1.41%10.48%
20155.31%-10.59%-2.14%-1.84%-2.23%6.19%13.29%-4.44%-7.52%1.69%-0.94%2.75%-2.71%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ASND is 64, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ASND is 6464
Overall Rank
The Sharpe Ratio Rank of ASND is 6464
Sharpe Ratio Rank
The Sortino Ratio Rank of ASND is 6363
Sortino Ratio Rank
The Omega Ratio Rank of ASND is 5959
Omega Ratio Rank
The Calmar Ratio Rank of ASND is 6868
Calmar Ratio Rank
The Martin Ratio Rank of ASND is 6767
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Ascendis Pharma A/S (ASND) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Ascendis Pharma A/S Sharpe ratios as of May 13, 2025 (values are recalculated daily):

  • 1-Year: 0.34
  • 5-Year: 0.06
  • 10-Year: 0.47
  • All Time: 0.44

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Ascendis Pharma A/S compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Ascendis Pharma A/S doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Ascendis Pharma A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ascendis Pharma A/S was 61.72%, occurring on Apr 28, 2023. The portfolio has not yet recovered.

The current Ascendis Pharma A/S drawdown is 15.50%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-61.72%Dec 15, 2020596Apr 28, 2023
-42.92%Jul 17, 2015225Jun 7, 2016165Feb 1, 2017390
-33.15%Feb 21, 202017Mar 16, 202046May 20, 202063
-30.77%Jun 4, 201990Oct 9, 201954Dec 26, 2019144
-27.69%Aug 28, 201882Dec 24, 201846Mar 4, 2019128

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Ascendis Pharma A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Ascendis Pharma A/S, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -4.9%.


-4.00-3.50-3.00-2.50-2.00-1.50-1.00-0.5020212022202320242025
-1.58
-1.51
Actual
Estimate

Valuation

The Valuation section provides an overview of how Ascendis Pharma A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ASND relative to other companies in the Biotechnology industry. Currently, ASND has a P/S ratio of 24.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ASND in comparison with other companies in the Biotechnology industry. Currently, ASND has a P/B value of 14.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items